Article (Scientific journals)
A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults
Werfel, T.; Lynch, V.; Asher, A. et al.
2016In Journal der Deutschen Dermatologischen Gesellschaft
Peer Reviewed verified by ORBi
 

Files


Full Text
A phase 2a proof of concept clinical trial to evaluate ZPL3893787.pdf
Publisher postprint (57.64 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
adult adverse; drug reaction; antiinflammatory activity; atopic dermatitis; body surface; clinical trial; controlled clinical trial; controlled study; cornea ulcer; double blind procedure; efficacy parameters; female human major clinical study; male parallel design phase 2 clinical trial; pruritus randomized controlled trial side effect; visually impaired person; endogenous compound; histamine H4 receptor; antagonist placebo
Abstract :
[en] It is well documented that histamine-induced inflammation is largely mediated through the H4 receptor (H4R). T lymphocytes and keratinocytes from patients with atopic dermatitis (AD) express high levels of H4R which mediate cytokine upregulation and histamine-induced proliferation. The identification of IL-17 positive cells in psoriatic lesions, and the fact that these cells expressed a functional H4R, lends weight to its therapeutic potential in inflammatory skin diseases such as AD and psoriasis. ZPL-389 is a low nanomolar and selective H4R antagonist.
Disciplines :
Dermatology
Author, co-author :
Werfel, T.;  Hannover Medical University, Germany > Departement of Dermatology
Lynch, V.;  MAC Clinical Research Ltd, Monarch House, Stourton, Leeds, United Kingdom
Asher, A.;  MAC Clinical Research Ltd, CityLabs, Manchester
Tsianakas, A.;  Universität Münster, Klinik für Hautkrankheiten, Germany > Dermatologie und Venerologie
Gupta, B.;  MAC Clinical Research Ltd, Faraday Way, Blackpool, United Kingdom
Sarmiento, R.
Ploszczuk, A.
Majorek-Olechowska, B.
Cimoszko, B.
NIKKELS, Arjen ;  Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service de dermatologie
Hofman, T.
Staubach, P.
Breuer, K.
Gawlik, A.
Buczylko, K.
Morren, MA.
Layton, G.
Yeadon, M.
Whitlock, L.
Purkins, L.
Liu, W.
More authors (11 more) Less
Language :
English
Title :
A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults
Publication date :
2016
Journal title :
Journal der Deutschen Dermatologischen Gesellschaft
ISSN :
1610-0379
eISSN :
1610-0387
Publisher :
Blackwell, Oxford, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 25 June 2019

Statistics


Number of views
366 (2 by ULiège)
Number of downloads
3 (1 by ULiège)

Bibliography


Similar publications



Contact ORBi